A key meeting for the pathology community
Organised by the French Society of Pathology (SFP), the Carrefour Pathologie 2025 congress took place from 19 to 21 November at the CNIT Forest in Paris La Défense. This annual event is one of the most important gatherings in the French-speaking pathology community, bringing together more than a thousand professionals to explore the latest advances in anatomical and cytological pathology.
Through conferences, symposiums, histoseminars and interactive sessions, Carrefour Pathologie offers a unique opportunity to discover the innovations shaping diagnosis, monitoring and patient care, particularly in respiratory diseases. The 2025 edition once again delivered a rich and diverse programme: thoracic pathology, theranostic markers, AI, national genomics initiatives, quality standards, ecological transition… key topics that reflect the evolving landscape of the discipline.
It was within this high-level scientific setting that the institut RespirERA was invited to present its work.
Pr Paul Hofman’s presentation: AI and a new biomarker in lung cancer
During a symposium dedicated to the contribution of artificial-intelligence algorithms in assessing predictive biomarkers in thoracic pathology, Pr Paul Hofman, Director of the institut RespirERA, presented a key innovation: the Quantitative Continuous Score (QCS).
A more precise measurement of TROP2 expression
The QCS is based on an AI algorithm applied to immunohistochemistry, offering a more refined analysis of TROP2 expression, an emerging protein of interest in thoracic oncology. This therapeutic target is attracting increasing attention, particularly in the development of novel treatments such as antibody-drug conjugates.
A major step forward for precision medicine
The work presented by Pr Hofman highlights the institut RespirERA’s commitment to integrating AI into pathological analysis to improve lung cancer care. This breakthrough aligns perfectly with the institute’s mission: developing innovative tools to better diagnose, predict and personalise treatments for respiratory diseases.
